News in Brief
Published: 14 October 2024
Nature Biotechnology
volume 42, page 1479 (2024)Cite this article
22 Accesses
2 Altmetric
Metrics details
In one week, the US Food and Drug Administration approved two treatments for Niemann–Pick disease type C (NPC). One agent, Miplyffa (arimoclomol) from Zevra Therapeutics, is the first drug approved by FDA to treat neurologic symptoms associated with NPC, in combination with the enzyme inhibitor miglustat. The other is IntraBio’s Aqneursa (levacetylleucine), an oral modified amino acid (N-acetyl-l-leucine) product that enhances cerebral glucose metabolism to reinvigorate mitochondrial ATP-related functions.
NPC is caused by mutations in NPC1 or NPC2 genes that result in abnormal lysosomal storage affecting cholesterol and lipid transport in cells, leading to progressive neurologic impairment and organ dysfunction. On average, people with NPC live for about 13 years, and until now, there was no approved therapy for this ultra-rare disease.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
Purchase on SpringerLink Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Log in
Learn about institutional subscriptions
Read our FAQs
Contact customer support
Rights and permissions About this article
Cite this article
Niemann–Pick double win.
Nat Biotechnol 42, 1479 (2024). https://doi.org/10.1038/s41587-024-02450-6
Download citation
Published: 14 October 2024
Issue Date: October 2024
DOI : https://doi.org/10.1038/s41587-024-02450-6
Information contained on this page is provided by an independent third-party content provider. This website makes no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact editor @pleasantgrove.business
